Clinical Trial Update: Niacin/Laropiprant and Endothelial Function [Phase 4]

View source ↗

Summary

Phase 4 trial update on the combination of niacin and laropiprant evaluating endothelial function in coronary artery disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Laropiprant (laropiprant)
• Niacin (nicotinic acid)

Snippet

Sponsor: University Medical Centre Ljubljana | Conditions: Coronary Heart Disease | Phase 4 | Status: COMPLETED